Absorption science

What The Blueberry Trials Actually Measured

The ingredients page names two blueberry trials in a single paragraph and moves on. This is the deep dive: what each trial actually measured, what 302 mg of anthocyanins and a cup of berries a day produced, and the question neither trial was designed to answer — how much of that pigment the body absorbs before it can do anything at all.

By Vinetaro Drops Team · Last updated September 30, 2026 · 10 min read · Absorption science · Reviewed by Dr. Renee Schwartz, ND

The two trials, read on their own terms

The Vinetaro Drops ingredients page photographs six plants around the bottle without naming any of them, and blueberry is the one item in that photograph whose circulation evidence comes with an actual number a reader can hold on to. That page gives the two trials a sentence each, inside an entry that has five other plants to cover. This article exists to do the opposite: to stop at blueberry and go through what each trial actually did, field by field, the way a reader would want if the pigment in that photograph were the only thing on the page.

Two separate human trials sit behind that entry, and they are worth keeping apart because they are not measuring the same thing. One is an acute, single-mechanism study of vascular function. The other is a six-month study of metabolic-syndrome biomarkers. A reader who conflates them ends up thinking blueberry research agrees with itself more neatly than it actually does.

What the acute vascular trial actually did

The acute trial is a double-blind, randomised, placebo-controlled study in healthy older adults, and its dose is the figure this site's ingredients page quotes: 26 g of freeze-dried wild blueberry powder a day, supplying 302 mg of anthocyanins. Twenty-six grams of powder is roughly a heaped tablespoon, reconstituted from a considerably larger fresh weight of berries, since freeze-drying removes most of the water.

The outcome measured was vascular function — the kind of endpoint researchers use to look at blood-vessel responsiveness over a short window, rather than a hard clinical outcome like a heart attack or a stroke. The trial also looked at cognitive performance in the same participants, which is a detail the ingredients page does not have room for and this article does: the study was designed around the idea that a single compound class, delivered acutely, might move two different systems at once.

Read from the trial as published. The last row is the gap this article is about, not an omission unique to this study — almost no anthocyanin efficacy trial reports it, for reasons the tracer section below explains.

What the six-month metabolic trial actually did

The second trial is a different kind of study entirely: a six-month, double-blind, randomised controlled trial in adults with metabolic syndrome, a cluster diagnosis that includes measures like waist circumference, blood pressure, fasting glucose and blood lipids. Where the acute trial asks what happens in the hours after one dose, this one asks what happens over half a year of daily intake.

The dose scaled up accordingly: 75 g and 150 g of freeze-dried blueberry equivalent a day, run as two separate arms against a control. Seventy-five grams of freeze-dried equivalent is roughly half a cup of fresh blueberries once the water content is accounted for; a hundred and fifty grams is roughly a full cup. Both are food-scale amounts eaten daily for six months, not a supplement-scale extract taken as a capsule or a drop.

• The trial ran in a population selected for existing metabolic risk, not in healthy volunteers.
• Two dose arms let the trial look for a dose-response relationship rather than a single yes-or-no result.
• Six months is long enough to look at biomarkers that do not move in an afternoon, which is the entire point of running a chronic rather than an acute design.
• Like the acute trial, the published result describes intake, not confirmed systemic exposure to the parent anthocyanins themselves.

Put the two trials side by side and a pattern appears that the ingredients page's single sentence per plant cannot show: this is a category where meaningful results have so far required either a concentrated acute dose or a sustained food-scale one. Nothing in the published record for this plant describes a small daily amount producing either kind of outcome.

What "absorbed" means for an anthocyanin

"302 mg of anthocyanins" is a statement about what went into a participant's mouth. It is not a statement about what reached general circulation intact, and the distance between those two numbers is the part of this story most supplement marketing skips past entirely.

Anthocyanins are water-soluble plant pigments, the compounds responsible for the red, purple and blue colours in blueberries, blackberries, red cabbage and a long list of other produce. Structurally they belong to the flavonoid family, and like most flavonoids they face a gauntlet between the mouth and the bloodstream: stomach acid, gut enzymes, the gut's own epithelial transport machinery, and a liver pass before anything reaches systemic circulation. Most of a dose is chemically altered, broken down by gut bacteria, or simply never crosses the gut wall before it is excreted.

This is not a property unique to blueberries or to this trial. It is a property of the anthocyanin class as a whole, and it is the reason nutrition scientists distinguish between the amount of a compound in a food, the amount that reaches the blood unchanged, and the amount of its metabolites — the altered forms the body produces from it — that eventually circulate. A dose figure like 302 mg answers the first question. It says nothing on its own about the second or third.

The tracer study: where the pigment actually goes

The most direct way to answer the absorption question is a tracer study, where the compound being studied is labelled with a stable, non-radioactive isotope so researchers can track exactly where it goes after it is swallowed. A 2013 study in the American Journal of Clinical Nutrition did exactly this with cyanidin-3-glucoside, one of the principal anthocyanins found in blueberries and many other dark-coloured fruits, using a carbon-13 label to follow the compound through human metabolism and elimination.

The finding that mattered was this: when every labelled form of the compound was added up — the untouched parent molecule plus every metabolite the body produced from it, recovered from blood, urine and breath — total absorption was considerably higher than earlier, cruder estimates had suggested. But the parent compound itself, unmetabolised cyanidin-3-glucoside circulating intact in blood, made up only a small fraction of that total. The great majority of what the body eventually processes from an anthocyanin dose is not the pigment a chemist would recognise on sight. It is what the gut microbiome and the liver turn it into.

That is the central fact this article exists to put next to the 302 mg figure. Trials that measure vascular function or metabolic markers after an anthocyanin-rich meal are measuring the net effect of the parent compound, its metabolites, and whatever else changed in the gut along the way. They are not, on their own, a measurement of how much of the ingested 302 mg survived intact to do the work.

Why a 2017 review had to say "more bioavailable than previously perceived"

A 2017 review in Annual Review of Food Science and Technology, co-authored by one of the researchers behind the tracer study above, took stock of exactly this confusion across the anthocyanin and flavanone literature. Its title says the finding plainly: anthocyanins and flavanones are more bioavailable than previously perceived, which is a review correcting the record on a figure that had been understated for years.

The correction runs in an unusual direction for this category. Earlier bioavailability estimates, often quoted as under one per cent of an ingested dose, looked only for the intact parent compound in blood and urine over a short window. Once metabolites were tracked properly, using methods like the carbon-13 approach above, total recovered material rose substantially. The review's point is not that anthocyanins are poorly absorbed in some absolute sense. It is that most of what the body does with them happens after a chemical transformation the earlier, cruder measurements could not see.

For a reader trying to weigh a trial dose against a bottle, the practical upshot of both papers together is the same: the pigment itself is a poor proxy for what actually circulates. A dose stated as milligrams of anthocyanins describes the starting material, not the active exposure, and that gap does not close by taking more of the starting material — it is a property of how the compound is handled by digestion, present at any dose.

What the metabolites might be doing instead

None of this means the acute and six-month trials measured nothing real. Vascular function moved and metabolic markers moved, in participants who ate real quantities of real blueberries under controlled conditions. The open scientific question is mechanistic, not whether an effect exists: which circulating substances, in what combination, produced it.

The leading explanation in the literature is that anthocyanin metabolites — and possibly the gut microbiome's own byproducts of fermenting the unabsorbed remainder — are doing meaningful biological work themselves, rather than being inert breakdown products on the way to excretion. That is a substantially more complicated story than "a pigment gets absorbed and acts," and it is one still being worked out study by study rather than one any single trial, including the two behind this site's ingredients page, has settled.

• The acute and six-month trials establish that real outcomes moved at real, food-scale intakes.
• The tracer study and the 2017 review establish that the active exposure is mostly metabolites, not the parent pigment.
• What is not yet established is a clean dose-response curve running from milligrams of anthocyanin consumed to milligrams of any one active metabolite in blood.
• That gap is a live research question across the flavonoid field generally, not a flaw specific to blueberry research.

Reading a food-scale trial dose against an unlabelled bottle

Vinetaro Drops carries no ingredient list, no Supplement Facts panel and no stated concentration of anything, blueberry included. The dropper-arithmetic article on this site works through what a two-drop, sixty-millilitre liquid routine can and cannot be expected to deliver in volume terms; this article is about a separate, upstream problem that exists even before volume enters the conversation.

The two blueberry trials behind this site's ingredients entry were run at 26 g of powder and at 75 to 150 g of freeze-dried equivalent a day — food quantities, eaten or drunk as food, not concentrated into a liquid extract at a stated ratio. Even setting the absorption question aside entirely, there is no published information connecting any liquid blueberry extract, at any concentration, to either of those trial doses. Layer the absorption question on top, and a second, independent gap opens: even a hypothetical dropper that somehow matched 302 mg of anthocyanins by weight would still not be delivering 302 mg of anything the tracer study found circulating intact.

What this page is not saying

This article is not a claim that blueberries, or the anthocyanins in them, do nothing. Two controlled human trials measured real outcomes at real intakes, and a growing body of bioavailability research is actively working out the mechanism behind those outcomes rather than disputing that they occurred. Nothing here should be read as a verdict on blueberry research generally.

It is also not a claim about this bottle's contents, because this bottle's printed surface makes no claim to compare against. Vinetaro Drops photographs blueberries on its marketing panel and states no amount, no extract ratio and no concentration for any plant pictured there. What this article adds to the ingredients page's single sentence is the specific, verifiable reason a milligram figure for an anthocyanin trial is a different kind of number from a milligram figure for, say, a mineral: most of it is metabolised before it becomes anything a vascular-function test can detect, and a dropper bottle with no stated concentration gives a reader nothing to measure that gap against in the first place.

References